Diabetes and periodontitis: the two-way street
The relationship runs in both directions, and the treatment-side evidence is real but modest, smaller than most patients are led to expect.
Diabetes and periodontal disease are unusual among the mouth-body connections in one respect: the relationship has been characterized as bidirectional for over thirty years, with support strong enough that periodontal disease is routinely described in the diabetes literature as a recognized complication of diabetes itself, not merely a correlated condition. That framing dates to 1993, when Harald Löe, then director of the National Institute of Dental Research, published "Periodontal Disease: The Sixth Complication of Diabetes Mellitus" in Diabetes Care, placing periodontal disease alongside retinopathy, neuropathy, nephropathy, and cardiovascular and peripheral vascular disease as a recognized consequence of poorly controlled diabetes.
The two directions
In one direction, diabetes worsens periodontal disease. Hyperglycemia drives the formation of advanced glycation end products (AGEs), which bind to receptors (RAGE) found on endothelial and inflammatory cells. This interaction promotes oxidative stress and a pro-inflammatory state, and in gingival tissue specifically it is associated with basement membrane thickening, altered angiogenesis, and increased tissue osmotic pressure, changes that impair the tissue's ability to resist and repair periodontal damage. A 2023 review in Diagnostics summarizing this literature states plainly that "diabetes mellitus has a detrimental effect on periodontal disease, increasing its prevalence, extent, and severity."
In the other direction, periodontitis worsens glycemic control. Periodontal infection is a source of chronic systemic inflammation, and successful periodontal treatment measurably reduces circulating inflammatory markers, including C-reactive protein and TNF-alpha, both of which interfere with insulin signaling when chronically elevated. The same review summarizes the net effect: "periodontitis negatively affects glycemic control and the course of diabetes," and treating it "may help to improve glucose control."
This is a genuinely bidirectional, mechanistically coherent relationship, not a one-way effect dressed up as two.
What the Cochrane review actually shows on HbA1c
The most rigorous synthesis of the treatment-side evidence is a Cochrane systematic review, most recently updated in 2022 by Terry C. Simpson and colleagues, covering 35 randomized controlled trials and 3,249 participants, most with type 2 diabetes. The review's central finding is that periodontal treatment produces a mean HbA1c reduction of 0.43 percentage points (95% CI: 0.28 to 0.59) at 3 to 4 months following treatment, based on 30 studies and 2,443 participants. The effect narrows to 0.30 percentage points at 6 months. The certainty of this evidence was graded moderate, downgraded one level because blinding of participants and clinical operators is not possible in a periodontal treatment trial by its nature. Only 2 of the 35 included studies were assessed as low risk of bias overall; 14 were high risk and 19 unclear.
Context matters here, and the honest brief has to supply it: a 0.43-point HbA1c reduction is real, but it is smaller than the 0.4 to 0.9 percentage point reduction typically produced by simply adding a second glucose-lowering medication to a treatment regimen. Periodontal therapy is not a substitute for pharmacologic diabetes management, and no credible reading of the Cochrane data supports treating it as one. What it supports is a meaningful adjunct: an intervention with a real, moderate-certainty effect size, delivered through a procedure that has independent value for oral health regardless of its glycemic effect.
Why endocrinologists and dentists rarely coordinate
Despite thirty years of established bidirectional evidence and a Cochrane-graded treatment effect, coordination between the two specialties that manage this relationship remains the exception rather than the rule. A 2018 survey of rural primary care physicians and dentists in North Dakota, published in Diabetes Spectrum by Fisketjon and Johnson, found that while 100% of respondents on both sides acknowledged the oral-systemic link in principle, referral behavior did not reflect that shared understanding: physicians referred patients with prediabetes or diabetes for dental evaluation more often than dentists referred patients with periodontal disease back to physicians, and the authors concluded there remains "an opportunity to promote interprofessional interaction through education about appropriate referral patterns."
A larger 2022 study in PLoS One by Al-Habib and colleagues, surveying 333 physicians, found that while awareness of the oral-systemic connection was high (92.8% agreed oral health is associated with systemic health, and 68.2% specifically agreed on a two-way relationship between periodontal disease and diabetes), only about half of physicians (50.8%) had referred any patient to a dentist in the past month, with no dedicated tracking of diabetes-specific referrals. The gap is not a knowledge gap. Physicians and dentists largely agree the relationship is real. It is a structural gap: separate intake systems, separate billing and insurance rails (medical versus dental), and no shared record that would prompt a referral at the point of care.
What integrated care would look like
The pieces already exist independently. Diabetes care visits could include a brief periodontal risk screen with a defined referral trigger, the way diabetic retinopathy screening is now a standard, billable part of primary care. Dental visits could include an HbA1c risk flag for undiagnosed diabetes, an approach that pilot programs have already tested with point-of-care screening in the dental chair. What is missing is not clinical willingness on either side, it is a shared record and a shared incentive to close the loop, since dental and medical care in the United States are financed, documented, and referred through entirely separate systems that were never designed to talk to each other.
What this means in practice
For a patient with diabetes, the practical takeaway is that periodontal treatment is worth pursuing for its own sake, with a real but modest secondary benefit to glycemic control, not a shortcut around medication. For providers, the honest position is that the biological case for coordination is stronger than the current infrastructure for it. Patients trying to understand what their coverage will actually pay for around a covered medical procedure with a dental dimension can check checkmydenial.com, and physicians managing diabetic patients who want to understand the coverage-side clearance standard for referring into dental care can see it laid out at premedicalcheck.com.
Sources
- Löe H. "Periodontal disease. The sixth complication of diabetes mellitus." Diabetes Care. 1993;16(1):329-334. https://pubmed.ncbi.nlm.nih.gov/8422804/
- Simpson TC, Clarkson JE, Worthington HV, et al. "Treatment of periodontitis for glycaemic control in people with diabetes mellitus." Cochrane Database of Systematic Reviews. 2022;(4):CD004714. https://pmc.ncbi.nlm.nih.gov/articles/PMC9009294/
- Păunică I, Giurgiu M, Dumitriu AS, et al. "The Bidirectional Relationship between Periodontal Disease and Diabetes Mellitus: A Review." Diagnostics (Basel). 2023;13(4):681. https://doi.org/10.3390/diagnostics13040681
- Fisketjon PM, Johnson EL. "Periodontal Disease and Diabetes: Perceptions, Communication, and Referral Between Rural Primary Care Physicians and Dentists." Diabetes Spectrum. 2018;31(2):193-195. https://doi.org/10.2337/ds17-0049
- Al-Habib F, et al. "Physicians' awareness of oral-systemic links and its association with physician-reported patient referral to dentists." PLoS One. 2022;17(10):e0276479. https://doi.org/10.1371/journal.pone.0276479